SCHEMBL207638

SCHEMBL207638

N[C@H](C(=O)O)c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.52
TDP1 Q9NUW8 4/20 0.52
MEN1 O00255 3/20 0.52
CYP2C9 P11712 3/20 0.52
KMT2A Q03164 3/20 0.52
CYP2C19 P33261 2/20 0.52
CYP2D6 P10635 1/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
DRD3 P35462 1/20 0.52
GRM4 Q14833 1/20 0.52
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 4/20 0.48
GRM1 Q13255 3/20 0.48
GRM2 Q14416 2/20 0.48
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL205545 1.00 HSD17B10 (0.52) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL162203 1.00 HSD17B10 (0.52) HSD17B10TDP1MEN1CYP2C9KMT2A
Hydrochloric Acid SCHEMBL28010750 0.98 HSD17B10 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
Hydrochloric Acid SCHEMBL23112808 0.98 HSD17B10 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
Hydrochloric Acid SCHEMBL23112807 0.98 HSD17B10 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL30057645 0.94 BCL2L1 (0.50) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL13527786 0.88 HSD17B10 (0.61) HSD17B10TDP1MEN1CYP2C9KMT2A
SCHEMBL6321555 0.82 HDAC3 (0.45) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL10069409 0.82 HDAC3 (0.45) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL5114354 0.82 HDAC3 (0.45) ALDH1A1HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6949658-B2 Process for producing optically active α-amino acid and optically active α-amino acid amide MITSUBISHI RAYON CO., LTD. (JP) 2005-09-27 US claimed
US-20030171597-A1 Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine MITSUBISHI RAYON CO., LTD. (JP) 2003-09-11 US claimed
EP-1300392-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-AMINO ACID AND OPTICALLY ACTIVE ALPHA-AMINO ACID AMIDE Mitsubishi Rayon Co., Ltd. (JP) 2003-04-09 EP claimed
EP-0968216-B1 PHOSPHINE LIGANDS WITH AMINO ACID GROUPS, METHOD FOR THEIR PRODUCTION AND USE THEREOF AS CATALYST COMPONENTS CELANESE CHEM EUROPE GMBH (DE) 2002-10-16 EP claimed
US-6300517-B1 SUITABLE AS CONSTITUENTS OF METAL COMPLEXES WHICH CAN BE USED AS CATALYSTS FOR REACTIONS TO FORM C--C, C--H, C--N, C--SI OR C--O BONDS CELANESE GMBH (DE) 2001-10-09 US claimed
US-6432953-B1 None US disclosed
CN-120202243-A Thermosetting resin composition, cured film, substrate, and electronic component 捷恩智株式会社 2025-06-24 CN disclosed
CN-116354924-B 2-Imidazolone derivative and application thereof 江苏恩华药业股份有限公司 2025-05-30 CN disclosed
CN-119367357-A Use of PSPH inhibitor in preparation of medicine for preventing, treating or improving nervous system diseases 中国医学科学院基础医学研究所 2025-01-28 CN disclosed
EP-4355755-A1 ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS Venatorx Pharmaceuticals, Inc. (US) 2024-04-24 EP disclosed
US-20240123078-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS VIVIDION THERAPEUTICS, INC. 2024-04-18 US disclosed
US-20240034753-A1 THERAPEUTIC PEPTIDES COHBAR, INC. 2024-02-01 US disclosed
CN-1180348-A Pyrrolidinyl hydroxamic acid compounds and their production process PFIZER (US) 1998-04-29 CN disclosed
US-5719147-A Morpholine and thiomorpholine tachykinin receptor antagonists MERCK & CO., INC. (US) 1998-02-17 US disclosed
EP-0817772-A1 PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS PFIZER INC. (US) 1998-01-14 EP disclosed
US-5691336-A ANTIINFLAMMATORY AGENTS; ANALGESICS; THERAPY OF ASTHMA, EMESIS MERCK & CO., INC. (US) 1997-11-25 US disclosed
EP-0804434-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LTD. (GB) 1997-11-05 EP disclosed
WO-1997018201-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1997-05-22 WO disclosed
WO-1996030339-A1 PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS PFIZER INC. (US) 1996-10-03 WO disclosed
WO-1996004274-A1 AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES MERCK SHARP & DOHME LIMITED (GB) 1996-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171597-A1 Process for producing optically active alpha-amino acid and optically active alpha-amino acid amine AADAT, BCAT1, BCAT2 HSD17B10 1536/4885TDP1 4133/4885MEN1 3310/4885
US-20240123078-A1 COMPOUNDS AND METHODS FOR MODULATING IMMUNE-RELATED PROTEINS CD4, ICOS, NFATC1 HSD17B10 3967/4885TDP1 3603/4885MEN1 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.